130 related articles for article (PubMed ID: 9168075)
1. Changes in serum estrogen levels in women during tamoxifen therapy.
Lum SS; Woltering EA; Fletcher WS; Pommier RF
Am J Surg; 1997 May; 173(5):399-402. PubMed ID: 9168075
[TBL] [Abstract][Full Text] [Related]
2. Effects of tamoxifen on the serum levels of oestrogens and adrenocortical steroids in postmenopausal breast cancer patients.
Wilking N; Carlström K; Sköldefors H; Theve NO; Wallgren A
Acta Chir Scand; 1982; 148(4):345-9. PubMed ID: 6215811
[TBL] [Abstract][Full Text] [Related]
3. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
5. Effect of tamoxifen treatment on estrogen metabolism in postmenopausal women with advanced breast cancer.
Levin J; Markham MJ; Greenwald ES; O'Connor JF; Zumoff B; Fukushima DK
Anticancer Res; 1982; 2(6):377-80. PubMed ID: 7168557
[TBL] [Abstract][Full Text] [Related]
6. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
7. [Serum estrone sulfate levels in patients with breast cancer].
Yasumura T; Oka T; Honjyo H; Okada H
Nihon Geka Gakkai Zasshi; 1988 Aug; 89(8):1267-72. PubMed ID: 3185494
[TBL] [Abstract][Full Text] [Related]
8. Endocrine status of premenopausal node-positive breast cancer patients following adjuvant chemotherapy and long-term tamoxifen.
Ravdin PM; Fritz NF; Tormey DC; Jordan VC
Cancer Res; 1988 Feb; 48(4):1026-9. PubMed ID: 3123050
[TBL] [Abstract][Full Text] [Related]
9. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
[TBL] [Abstract][Full Text] [Related]
10. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients.
Mandalà M; Moro C; Ferretti G; Calabro MG; Nolè F; Rocca A; Munzone E; Castro A; Curigliano G
Anticancer Res; 2001; 21(1B):585-8. PubMed ID: 11299809
[TBL] [Abstract][Full Text] [Related]
11. Endocrine effects of adjuvant letrozole + triptorelin compared with tamoxifen + triptorelin in premenopausal patients with early breast cancer.
Rossi E; Morabito A; De Maio E; Di Rella F; Esposito G; Gravina A; Labonia V; Landi G; Nuzzo F; Pacilio C; Piccirillo MC; D'Aiuto G; D'Aiuto M; Rinaldo M; Botti G; Gallo C; Perrone F; de Matteis A
J Clin Oncol; 2008 Jan; 26(2):264-70. PubMed ID: 18086795
[TBL] [Abstract][Full Text] [Related]
12. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.
De Marinis L; Mancini A; Izzi D; Bianchi A; Giampietro A; Fusco A; Liberale I; Rossi S; Valle D
Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871
[TBL] [Abstract][Full Text] [Related]
14. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.
Manni A; Pearson OH
Cancer Treat Rep; 1980; 64(6-7):779-85. PubMed ID: 6775808
[TBL] [Abstract][Full Text] [Related]
16. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
[TBL] [Abstract][Full Text] [Related]
17. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
[TBL] [Abstract][Full Text] [Related]
18. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC).
Kaaks R; Berrino F; Key T; Rinaldi S; Dossus L; Biessy C; Secreto G; Amiano P; Bingham S; Boeing H; Bueno de Mesquita HB; Chang-Claude J; Clavel-Chapelon F; Fournier A; van Gils CH; Gonzalez CA; Gurrea AB; Critselis E; Khaw KT; Krogh V; Lahmann PH; Nagel G; Olsen A; Onland-Moret NC; Overvad K; Palli D; Panico S; Peeters P; Quirós JR; Roddam A; Thiebaut A; Tjønneland A; Chirlaque MD; Trichopoulou A; Trichopoulos D; Tumino R; Vineis P; Norat T; Ferrari P; Slimani N; Riboli E
J Natl Cancer Inst; 2005 May; 97(10):755-65. PubMed ID: 15900045
[TBL] [Abstract][Full Text] [Related]
19. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
20. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients.
Rose DP; Davis TE
Cancer Res; 1980 Nov; 40(11):4043-7. PubMed ID: 6451282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
